Pharmacokinetics of recombinant factor IX in relation to age of the patient: Implications for dosing in prophylaxis

Haemophilia

Volumn 7, Issue 2, 2001, Pages 133-139

  Bjorkman S ^a,b   Shapiro, A D ^a,b   Berntorp, E ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

Author keywords

Cost effectiveness; Dosage; Factor IX; Haemophilia B; Pharmacokinetics; Prophylaxis

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADOLESCENCE; ADOLESCENT; ADULT; ADULTHOOD; ARTICLE; BODY WEIGHT; CHILD; CHILDHOOD; COMPUTER SIMULATION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG USE; HEMOPHILIA B; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STEADY STATE;

ADOLESCENT; ADULT; AGE FACTORS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; FACTOR IX; HEMOPHILIA B; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 0035081112     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2001.00465.x     Document Type: Article

References (14)

1. Recombinant factor IX
2. Biochemical characterization of recombinant factor IX
3. Clinical evaluation of recombinant factor IX
4. The pharmacokinetics of factor VIII and factor IX. Methodology, pitfalls and applications
5. Should clearance be normalised to body surface or to lean body mass?
6. Anthropometric evaluation of body composition throughout life
7. Pharmacokinetic dosing in prophylactic treatment of hemophilia A
8. Multidose pharmacokinetics of factor IX. Implications for dosing in prophylaxis
9. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A
10. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation
11. Call for post-licensing human pharmacokinetic studies of administration of recombinant factor IX
12. Twenty-five years experience of prophylactic treatment in severe haemophilia A and B
13. Relationships among liver and kidney volumes, lean body mass and drug clearance
14. Lean body mass as a predictor of drug dosage. Implications for drug therapy